Odds of Advanced Cancer, Breast Cancer Death Lower in Screen-Detected Disease
By Elana Gotkine HealthDay Reporter
THURSDAY, June 5, 2025 -- For patients aged 40 years or older, screen-detected breast cancer is associated with lower odds of advanced cancer, mastectomy, and breast cancer-related death, according to a study published online May 30 in Radiology: Imaging Cancer.
Javeria Munir, M.D., from the University of Ottawa in Ontario, Canada, and colleagues conducted a retrospective observational cohort study involving consecutive women aged 40 years or older diagnosed with breast cancer between January and December 2016 to examine the impact of method of detection (screen-detected versus symptom-detected) on pathologic stage, surgical treatment, and chemotherapy.
The study included 821 patients, with a mean duration of follow-up of 6.7 years. The researchers found that symptom-detected cancers were more frequent in less-screened age groups than in screened age groups (72.9 and 70.4 percent versus 49.5 and 33.3 percent for those aged 40 to 49 and 75 years and older versus 50 to 59 and 60 to 74 years, respectively). The odds of advanced cancer (stage IIA or greater) were higher with symptom detection versus screen detection (32.5 versus 10.2 percent; odds ratio, 6.60). After adjustment for age and stage at diagnosis, a higher risk for breast cancer-related death was seen for symptom-detected cancers (hazard ratio, 1.63) and the odds of mastectomy were also higher (odds ratio, 2.20), while the odds of chemotherapy were the same. Higher tumor stage was significantly associated with symptom detection, greater risk for chemotherapy, and age at diagnosis in a multivariable analysis.
“Within only 6.7 years of follow-up, almost 20 percent of the 821 breast cancer patients had died, half of them from breast cancer,” lead study author Jean M. Seely, M.D., also from the University of Ottawa, said in a statement. “The patients whose breast cancers were detected because of symptoms had a 63 percent higher likelihood of dying. The results of this study will likely support the move to reduce the breast cancer screening age to 40 in the U.S. and Canada."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-06-06 06:00
Read more

- Stealth BioTherapeutics Announces “Path Forward” Despite Disappointing Delay for Ultra-Rare Barth Syndrome
- Pepto Bismol May Not Prevent Traveler’s Diarrhea, New Study Finds
- Johnson & Johnson Unveils First-in-Human Results for Pasritamig, Showing Early Anti-Tumor Activity in Prostate Cancer
- Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis
- Pheast Therapeutics Receives FDA Fast Track Designation for PHST001 for the Treatment of Ovarian Cancer
- Longer In-Bed Time Linked to Small Vessel Disease Burden in TIA/Mild Stroke
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions